
3. SUMMARY

Provided herein are pharmaceutical dosage forms of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione ("Compound A"), or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof. Also provided herein are methods of treating, managing, or preventing diseases and conditions such as, but not limited to, cancer, pain, Macular Degeneration, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis, a sleep disorder, hemoglobinopathy, anemia, an inflammatory disease, an autoimmune disease, a viral disease, a genetic disease, an allergic disease, a bacterial disease, an ocular neovascular disease, a choroidal neovascular disease, a retina neovascular disease, and rubeosis, using Compound A, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate thereof, in the dosage forms described herein.

In one aspect, the present disclosure refers to a tablet comprising:

(A) a core composition, wherein the core composition comprises:

(i) compound A



(A)

or a pharmaceutically acceptable salt thereof, at an amount of about 10% by weight of the total core composition;

(ii) lactose at an amount of about 60% by weight of the total core composition;

(iii) microcrystalline cellulose at an amount of about 26.25% by weight of the total core composition;

(iv) croscarmellose at an amount of about 3% by weight of the total core composition; and

(v) magnesium stearate at an amount of about 0.75% by weight of the total core composition; and

(B) a coating formulation, wherein the coating formulation comprises:

(i) polyvinyl alcohol at an amount of about 40% by weight of the total coating formulation;


(ii) polyethylene glycol at an amount of about 20% by weight of the total coating formulation;

(iii) talc at an amount of about 15% by weight of the total coating formulation; and

(iv) a mixture of coloring agents at an amount of about 25% by weight of the total coating formulation.

In another aspect, the present disclosure refers to a use of the tablet disclosed herein in the manufacture of a medicament for treating, preventing or managing a disease or disorder, wherein the disease or disorder is psoriasis, arthritis, dermatitis, acne, dermatomyositis, ulcerative colitis, Behcet's disease, Crohn's disease, sarcoidosis, uveitis, rosacea or lichen planus.

In yet another aspect, the present disclosure refers to a use of compound A



(A)

or a pharmaceutically acceptable salt thereof, in the preparation of a tablet for treating, preventing or managing a disease or disorder,

wherein the disease or disorder is psoriasis, arthritis, dermatitis, acne, dermatomyositis, ulcerative colitis, Behcet's disease, Crohn's disease, sarcoidosis, uveitis, rosacea or lichen planus,

wherein the tablet comprises:

(A) a core composition, wherein the core composition comprises:

(i) the compound (A) or the pharmaceutically acceptable salt thereof, at an amount of about 10% by weight of the total core composition; (ii) lactose at an amount of about 60% by weight of the total core composition;

(iii) microcrystalline cellulose at an amount of about 26.25% by weight of the total core composition;

(iv) croscarmellose at an amount of about 3% by weight of the total core composition; and

(v) magnesium stearate at an amount of about 0.75% by weight of the total core composition; and

(B) a coating formulation, wherein the coating formulation comprises:

(i) polyvinyl alcohol at an amount of about 40% by weight of the total coating formulation;

(ii) polyethylene glycol at an amount of about 20% by weight of the total coating formulation;


(iii) talc at an amount of about 15% by weight of the total coating formulation; and

(iv) a mixture of coloring agents at an amount of about 25% by weight of the total coating formulation.

4. DETAILED DESCRIPTION

4.1 Definitions

As used herein, the term "Compound A" refers to enantiomerically pure 2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione. Without being limited by theory, Compound A is believed to be (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione, which has the following structure:



Compound A

As used herein and unless otherwise indicated, a composition that is "substantially free" of a compound means that the composition contains less than about 20 percent by weight, more preferably less than about 10 percent by weight, even more preferably less than about 5 percent by weight, and most preferably less than about 3 percent by weight of the compound.


As used herein and unless otherwise indicated, the term "stereomerically pure" means a composition that comprises one stereoisomer of a compound and is substantially

What is claimed is:

1. A tablet comprising:

(A) a core composition, wherein the core composition comprises:

(i) compound A



(A)

or a pharmaceutically acceptable salt thereof, at an amount of about 10% by weight of the total core composition;

(ii) lactose at an amount of about 60% by weight of the total core composition;

(iii) microcrystalline cellulose at an amount of about 26.25% by weight of the total core composition;

(iv) croscarmellose at an amount of about 3% by weight of the total core composition; and

(v) magnesium stearate at an amount of about 0.75% by weight of the total core composition; and

(B) a coating formulation, wherein the coating formulation comprises:

(i) polyvinyl alcohol at an amount of about 40% by weight of the total coating formulation;

(ii) polyethylene glycol at an amount of about 20% by weight of the total coating formulation;

(iii) talc at an amount of about 15% by weight of the total coating formulation; and

(iv) a mixture of coloring agents at an amount of about 25% by weight of the total coating formulation.

2. Use of the tablet of claim 1 in the manufacture of a medicament for treating, preventing or managing a disease or disorder, wherein the disease or disorder is psoriasis, arthritis, dermatitis, acne, dermatomyositis, ulcerative colitis, Behcet's disease, Crohn's disease, sarcoidosis, uveitis, rosacea or lichen planus.


3. The use of claim 2, wherein the psoriasis is plaque-type psoriasis.

4. The use of claim 2, wherein the arthritis is psoriatic arthritis, rheumatoid arthritis, osteoarthritis or acute gouty arthritis.

5. The use of claim 2, wherein the dermatitis is atopic dermatitis or contact dermatitis.

6. The use of claim 2, wherein the sarcoidosis is chronic cutaneous sarcoidosis.

7. Use of compound A



(A)

or a pharmaceutically acceptable salt thereof, in the preparation of a tablet for treating, preventing or managing a disease or disorder,

wherein the disease or disorder is psoriasis, arthritis, dermatitis, acne, dermatomyositis, ulcerative colitis, Behcet's disease, Crohn's disease, sarcoidosis, uveitis, rosacea or lichen planus,

wherein the tablet comprises:

(A) a core composition, wherein the core composition comprises:

(i) the compound (A) or the pharmaceutically acceptable salt thereof, at an amount of about 10% by weight of the total core composition; (ii) lactose at an amount of about 60% by weight of the total core composition;

(iii) microcrystalline cellulose at an amount of about 26.25% by weight of the total core composition;

(iv) croscarmellose at an amount of about 3% by weight of the total core composition; and

(v) magnesium stearate at an amount of about 0.75% by weight of the total core composition; and

(B) a coating formulation, wherein the coating formulation comprises:

(i) polyvinyl alcohol at an amount of about 40% by weight of the total coating formulation;

(ii) polyethylene glycol at an amount of about 20% by weight of the total coating formulation;

(iii) talc at an amount of about 15% by weight of the total coating formulation; and

(iv) a mixture of coloring agents at an amount of about 25% by weight of the total coating formulation.

8. The use of claim 7, wherein the psoriasis is plaque-type psoriasis.

9. The use of claim 7, wherein the arthritis is psoriatic arthritis, rheumatoid arthritis, osteoarthritis or acute gouty arthritis.

10. The use of claim 7, wherein the dermatitis is atopic dermatitis or contact dermatitis.

11. The use of claim 7, wherein the sarcoidosis is chronic cutaneous sarcoidosis.